Medtronic, Tempus testing AI to find potential TAVR patients

MedTech Dive November 25, 2024
Nick Paul Taylor

The randomized trial will use Tempus’ platform to find patients who are eligible for interventions such as TAVR but do not have a treatment plan in place.

Dive Brief:

• Medtronic and Tempus have begun a study to assess the use of artificial intelligence to identify patients with symptomatic severe aortic stenosis, the companies said last week.
• The randomized trial will use Tempus’ platform to find patients who are eligible for interventions such as transcatheter aortic valve replacement (TAVR) but do not have a treatment plan in place. The study is funded by Medtronic and sponsored by Tempus.
• Identifying patients could address the undertreatment of symptomatic severe aortic stenosis, which can be fatal, and tackle racial, ethnic, gender and geographic...

Today's Sponsors

Today's Sponsor